Aeglea raises $50M in IPO after slashing share price

John Carroll Austin, TC-based Aeglea BioTherapeutics raised $ 50 million in its IPO after pricing 5 million shares at $ 10 each, far below the range that it had set out for itself. FierceBiotech ...

Merck sets $54K list price for hep C combo as it preps for battle with Gilead, AbbVie

Carly Helfand Industry watchers have long been speculating on how Merck would take on heavyweights Gilead and AbbVie when it priced its new hep C regimen. And now, they have their answer: ...

What public outcry? New year brings dozens of double-digit drug price hikes

Tracy Staton All eyes may be on rising drug costs, but that doesn't mean pharma companies are backing away from price hikes. In recent days, analysts have spotlighted hundreds of ...

Drug price increases saw ‘high water mark’ year in 2015: Analysts

Emily Wasserman Price hikes have landed pharma in hot water lately, with lawmakers, the public and presidential hopefuls lashing out at companies over skyrocketing costs. But things ...

Big Pharma’s steady double-digit price hikes cost Medicare billions

Tracy Staton A new report from the Center for Medicare and Medicaid Services highlights some commonly used meds whose sales growth–and Medicare spending–depends more on ...

Bristol-Myers puts a blockbuster $142K price on new cancer med Empliciti

Carly Helfand After winning FDA approval Monday, the latest multiple myeloma treatment–Empliciti, from Bristol-Myers Squibb and AbbVie–is about to hit the scene. And like ...

GOP’s Rubio joins the pharma-bashing trend, slamming ‘profiteering’ on price hikes

Tracy Staton The drug-pricing debate has moved to the Republican side of the aisle. GOP candidate Sen. Marco Rubio joined the fray in New Hampshire over the weekend, by slamming "pure ...

COMMENTARY: Why would Martin Shkreli hike an old drug price by 5000%? Only a ‘moron’ would ask

John Carroll FierceBiotech News

Report: Baxalta’s $2B plot to buy Ariad broke down over price

Damian Garde Last week's buzz that Baxalta, angling to shake off some unwanted buyout attention from Shire, had set sights on Ariad Pharmaceuticals sent the latter company's ...

Report: Real-world Blincyto spending likely to fall far short of Amgen’s $178K list price

Tracy Staton When Amgen rolled out its Blincyto treatment for an ultra-rare form of leukemia, the California biotech set what seemed to be an eye-watering price–$ 178,000 ...

Lilly, Sanofi, Novo among many pharma players to throw off big price gains in H1

Eric Palmer The first half of the year has provided a good ride for Big Pharma and its investors with indices up in the U.S. and Europe. Even Japanese drugmakers avoided the side effects ...

Probing lawmakers grill Valeant on price hikes

Carly Helfand A pair of lawmakers is taking a look into recent drug price increases–and as part of the investigation, it wants some information from Valeant. FiercePharma News
Page 1 of 41234
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS